RE:RE:RE:RE:RE:RE:Could shiseido be waiting for dermal injector?Hi Inv3strr:-
If Shiseido made an offer before March 1, 2020 (say 15 dollars), I would assume that the warrant holders would have the right to convert their warrants (2 dollars coversion price) to common shares. Although the conversion would add 5.4 million dollars to Replicel's bank account, it would cost Shiseido 13 dollars net times 2.7 million shares or 35.1 million extra to buy the Company before March 1, 2020.
I think this is a possibility because we are not that far away from March 1, 2020. There is nothing stopping Shiseido from entering into negotiations with Replicel now with the intention of pulling the trigger after the warrants expire.
As I have mentioned before, Shiseido's behaviour is far from the type you want in a partner. I would be very reluctant to negotiate a licencing agreement with Shiseido for RCH01 Rights for the remainder of the World. Shiseido only have the Rights for Asia and I haven't noticed too many bald Asian males (compared to non-Asians) in the Greater Toronto Area where I live. Also, most Asian males and females (in Asia) who do have hair loss issues are not in a position to afford the product. The big money for this product will be made from customers in the West.
After looking at the results from the Phase 2 Trial, Replicel should 'suggest' to Shiseido to make an offer for the entire Company in order to secure all Rights.
Wishful thinking????